Relative Resistance of HIV-1 Founder Viruses to Control by Interferon-alpha

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2013 Dec 5

PMID 24299076

Citations 139

Authors

Angharad E Fenton-May

Oliver Dibben

Tanja Emmerich

Haitao Ding

Katja Pfafferott

Marlen M Aasa-Chapman

Pierre Pellegrino

Ian Williams

Myron S Cohen

Feng Gao

George M Shaw

Beatrice H Hahn

Christina Ochsenbauer

John C Kappes

Persephone Borrow

Affiliations

Soon will be listed here.

Abstract

Background: Following mucosal human immunodeficiency virus type 1 (HIV-1) transmission, type 1 interferons (IFNs) are rapidly induced at sites of initial virus replication in the mucosa and draining lymph nodes. However, the role played by IFN-stimulated antiviral activity in restricting HIV-1 replication during the initial stages of infection is not clear. We hypothesized that if type 1 IFNs exert selective pressure on HIV-1 replication in the earliest stages of infection, the founder viruses that succeed in establishing systemic infection would be more IFN-resistant than viruses replicating during chronic infection, when type 1 IFNs are produced at much lower levels. To address this hypothesis, the relative resistance of virus isolates derived from HIV-1-infected individuals during acute and chronic infection to control by type 1 IFNs was analysed.

Results: The replication of plasma virus isolates generated from subjects acutely infected with HIV-1 and molecularly cloned founder HIV-1 strains could be reduced but not fully suppressed by type 1 IFNs in vitro. The mean IC50 value for IFNα2 (22 U/ml) was lower than that for IFNβ (346 U/ml), although at maximally-inhibitory concentrations both IFN subtypes inhibited virus replication to similar extents. Individual virus isolates exhibited differential susceptibility to inhibition by IFNα2 and IFNβ, likely reflecting variation in resistance to differentially up-regulated IFN-stimulated genes. Virus isolates from subjects acutely infected with HIV-1 were significantly more resistant to in vitro control by IFNα than virus isolates generated from the same individuals during chronic, asymptomatic infection. Viral IFN resistance declined rapidly after the acute phase of infection: in five subjects, viruses derived from six-month consensus molecular clones were significantly more sensitive to the antiviral effects of IFNs than the corresponding founder viruses.

Conclusions: The establishment of systemic HIV-1 infection by relatively IFNα-resistant founder viruses lends strong support to the hypothesis that IFNα plays an important role in the control of HIV-1 replication during the earliest stages of infection, prior to systemic viral spread. These findings suggest that it may be possible to harness the antiviral activity of type 1 IFNs in prophylactic and potentially also therapeutic strategies to combat HIV-1 infection.

Citing Articles

Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction.

Gaba A, Yousefi M, Bhattacharjee S, Chelico L J Virol. 2024; 99(1):e0160624.

PMID: 39714157 PMC: 11784016. DOI: 10.1128/jvi.01606-24.

Functional variability of Nef in antagonizing SERINC5 during acute to chronic HIV-1 infection.

Li W, Li G, Liu Y, Meng L, Zhang T, Wang L AIDS. 2024; 39(3):229-240.

PMID: 39612239 PMC: 11784911. DOI: 10.1097/QAD.0000000000004079.

Host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1.

Itell H, Guenthoer J, Humes D, Baumgarten N, Overbaugh J Nat Microbiol. 2024; 9(11):2985-2996.

PMID: 39363105 DOI: 10.1038/s41564-024-01806-7.

The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.

Marchitto L, Richard J, Prevost J, Tauzin A, Yang D, Chiu T J Virol. 2024; 98(10):e0101624.

PMID: 39248460 PMC: 11495009. DOI: 10.1128/jvi.01016-24.

MITOCHONDRIAL ANTIVIRAL PATHWAYS CONTROL ANTI-HIV RESPONSES AND ISCHEMIC STROKE OUTCOMES VIA THE RIG-1 SIGNALING AND INNATE IMMUNITY MECHANISMS.

Torices S, Moreno T, Ramaswamy S, Naranjo O, Teglas T, Osborne O bioRxiv. 2024; .

PMID: 38895303 PMC: 11185786. DOI: 10.1101/2024.06.07.598027.

References

Edlin B, St Clair M, Pitha P, Whaling S, King D, Bitran J . In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med. 1992; 117(6):457-60. DOI: 10.7326/0003-4819-117-6-457. View

Pincetic A, Kuang Z, Seo E, Leis J . The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. J Virol. 2010; 84(9):4725-36. PMC: 2863725. DOI: 10.1128/JVI.02478-09. View

von Sydow M, Sonnerborg A, Gaines H, Strannegard O . Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses. 1991; 7(4):375-80. DOI: 10.1089/aid.1991.7.375. View

Roy S, Katze M, Parkin N, Edery I, Hovanessian A, Sonenberg N . Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product. Science. 1990; 247(4947):1216-9. DOI: 10.1126/science.2180064. View

Boue F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R . Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS. 2010; 25(1):115-8. DOI: 10.1097/QAD.0b013e328340a1e7. View

Zaunders J, Dyer W, Churchill M . The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control. Curr Opin HIV AIDS. 2011; 6(3):151-6. DOI: 10.1097/COH.0b013e3283454d5b. View

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

Van Damme N, Goff D, Katsura C, Jorgenson R, Mitchell R, Johnson M . The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008; 3(4):245-52. PMC: 2474773. DOI: 10.1016/j.chom.2008.03.001. View

Rempel H, Sun B, Calosing C, Pillai S, Pulliam L . Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS. 2010; 24(10):1415-23. PMC: 2991092. DOI: 10.1097/QAD.0b013e32833ac623. View

10.

Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M . Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A. 2010; 107(21):9843-8. PMC: 2906837. DOI: 10.1073/pnas.0911932107. View

11.

Stark G, Kerr I, Williams B, Silverman R, Schreiber R . How cells respond to interferons. Annu Rev Biochem. 1998; 67:227-64. DOI: 10.1146/annurev.biochem.67.1.227. View

12.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

13.

Yan N, Regalado-Magdos A, Stiggelbout B, Lee-Kirsch M, Lieberman J . The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol. 2010; 11(11):1005-13. PMC: 2958248. DOI: 10.1038/ni.1941. View

14.

Tavel J, Huang C, Shen J, Metcalf J, Dewar R, Shah A . Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res. 2010; 30(7):461-4. PMC: 2964361. DOI: 10.1089/jir.2009.0090. View

15.

Malim M . APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci. 2008; 364(1517):675-87. PMC: 2660912. DOI: 10.1098/rstb.2008.0185. View

16.

Freel S, Picking R, Ferrari G, Ding H, Ochsenbauer C, Kappes J . Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol. 2012; 86(12):6835-46. PMC: 3393529. DOI: 10.1128/JVI.00437-12. View

17.

Lu J, Pan Q, Rong L, He W, Liu S, Liang C . The IFITM proteins inhibit HIV-1 infection. J Virol. 2010; 85(5):2126-37. PMC: 3067758. DOI: 10.1128/JVI.01531-10. View

18.

Smith M, Dean M, Carrington M, Winkler C, Huttley G, Lomb D . Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City.... Science. 1997; 277(5328):959-65. DOI: 10.1126/science.277.5328.959. View

19.

Lepelley A, Louis S, Sourisseau M, Law H, Pothlichet J, Schilte C . Innate sensing of HIV-infected cells. PLoS Pathog. 2011; 7(2):e1001284. PMC: 3040675. DOI: 10.1371/journal.ppat.1001284. View

20.

Teijaro J, Ng C, Lee A, Sullivan B, Sheehan K, Welch M . Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013; 340(6129):207-11. PMC: 3640797. DOI: 10.1126/science.1235214. View